NEWS
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN) has initiated the PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray for the acute treatment of social anxiety disorder (SAD). This marks a significant milestone in the company's registration-directed PALISADE Phase 3 program. Fasedienol is designed for non-systemic, rapid activation of nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.
CEO Shawn Singh highlighted the potential of fasedienol to provide a transformative acute treatment optionfor over 30 million Americans suffering from SAD, which is associated with increased risk for depression, alcohol abuse, and suicide attempts. Notably, current FDA-approved pharmacological therapies do not include an acute treatment option for SAD.
CEO Shawn Singh highlighted the potential of fasedienol to provide a transformative acute treatment optionfor over 30 million Americans suffering from SAD, which is associated with increased risk for depression, alcohol abuse, and suicide attempts. Notably, current FDA-approved pharmacological therapies do not include an acute treatment option for SAD.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2311Followers
105Following
24KVisitors
Follow